> Detailanzeige

Rochefort, Juliette; Karagiannidis, Ioannis; Baillou, Claude; Belin, Lisa; Guillot-Delost, Maude; Macedo, Rodney; Le Moignic, Aline; Mateo, Véronique; Soussan, Patrick; Brocheriou, Isabelle; Teillaud, Jean-Luc; Dieu-Nosjean, Marie-Caroline; Bertolus, Chloé; Lemoine, Francois Michel; Lescaille, Géraldine

Defining biomarkers in oral cancer according to smoking and drinking status

Literatur-
verwaltung

Zur
Merkliste

Lösche von
Merkliste

Per Whatsapp teilen

Schließen

Merkliste



Sie können Bookmarks mittels Listen verwalten, loggen Sie sich dafür bitte in Ihr SLUB Benutzerkonto ein.
  • Medientyp: E-Artikel
  • Titel: Defining biomarkers in oral cancer according to smoking and drinking status
  • Beteiligte: Rochefort, Juliette; Karagiannidis, Ioannis; Baillou, Claude; Belin, Lisa; Guillot-Delost, Maude; Macedo, Rodney; Le Moignic, Aline; Mateo, Véronique; Soussan, Patrick; Brocheriou, Isabelle; Teillaud, Jean-Luc; Dieu-Nosjean, Marie-Caroline; Bertolus, Chloé; Lemoine, Francois Michel; Lescaille, Géraldine
  • Erschienen: Frontiers Media SA, 2023
  • Erschienen in: Frontiers in Oncology
  • Sprache: Nicht zu entscheiden
  • DOI: 10.3389/fonc.2022.1068979
  • ISSN: 2234-943X
  • Schlagwörter: Cancer Research ; Oncology
  • Entstehung:
  • Anmerkungen:
  • Beschreibung: <jats:sec><jats:title>Introduction</jats:title><jats:p>Oral Squamous Cell Carcinomas (OSCC) are mostly related to tobacco consumption eventually associated to alcohol (Smoker/Drinker patients: SD), but 25-30% of the patients have no identified risk factors (Non-Smoker/Non-Drinker patients: NSND). We hypothesized that these patients have distinguishable immune profiles that could be useful for prognosis.</jats:p></jats:sec><jats:sec><jats:title>Materials and Methods</jats:title><jats:p>Cells present in immune tumor microenvironment (TME) and blood from 87 OSCC HPV-negative patients were analyzed using a multiparameter flow cytometry assay, in a prospective case-control study. Cytokine levels in tumor supernatants and blood were determined by a cytometric bead array (CBA) assay.</jats:p></jats:sec><jats:sec><jats:title>Results</jats:title><jats:p>Normal gingiva and blood from healthy donors (HD) were used as controls. A significant increase of granulocytes (p&amp;lt;0.05 for blood), of monocytes-macrophages (p&amp;lt;0.01 for blood) and of CD4<jats:sup>+</jats:sup> T cells expressing CD45RO and CCR6 (p&amp;lt;0.001 for blood; p&amp;lt;0.0001 for TME) as well as higher levels of IL-6 (p&amp;lt;0.01 for sera, p&amp;lt;0.05 for tumor supernatant) were observed in SD patients as compared to NSND OSCC patients and HD. High percentages of CD4<jats:sup>+</jats:sup> T cells expressing CD45RO and CCR6 cells in tumor tissue (p=0.05) and blood (p=0.05) of SD OSCC patients were also associated with a poorer prognosis while a high percentage of regulatory T cells (Treg) in tumor tissue was associated with a more favorable prognostic factor (p=0.05). Also, a higher percentage of blood CD8<jats:sup>+</jats:sup> T lymphocytes among CD45<jats:sup>+</jats:sup> cells in NSND patients was associated with a better disease-free survival (p=0.004).</jats:p></jats:sec><jats:sec><jats:title>Conclusion</jats:title><jats:p>Granulocytes, monocytes-macrophages, and CD4<jats:sup>+</jats:sup> T cells expressing CD45RO and CCR6 in blood and TME as well as serum IL-6 can therefore distinguish OSCC SD and NSND patients. Quantifying the proportion of CD4<jats:sup>+</jats:sup> T cells expressing CD45RO and CCR6 and of Treg in SD patients and CD8<jats:sup>+</jats:sup> T cells in NSND patients could help defining the prognostic of OSCC patients.</jats:p></jats:sec>
  • Zugangsstatus: Freier Zugang